


RealRate

PHARMACEUTICAL 2018

Catalent Inc. Rank 20 of 349





PHARMACEUTICAL 2018



Catalent Inc. Rank 20 of 349

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 445% points. The greatest weakness of Catalent Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 467% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	1,059,800
Cost of Goods Sold	0
Intangible Assets	1,317,200
Liabilities, Current	469,000
Liabilities, Non-Current	0
Other Assets	81,400
Other Compr. Net Income	-8,400
Other Expenses	1,454,600
Other Liabilities	0
Other Net Income	-108,400
Property and Equipment	995,900
Research and Development	0
Revenues	2,075,400
Selling, General and Administrative Expense	402,600

Output Variable	Value in 1000 USD
Assets	3,454,300
Liabilities	469,000
Expenses	1,857,200
Stockholders Equity	2,985,300
Net Income	109,800
Comprehensive Net Income	105,600
Economic Capital Ratio	189%